Valuation models
price $466.01 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused406.96 – 739.82530.4612% undervaluedDCF · Perpetuity growth · 10y431.72 – 775.06559.1917% undervaluedDCF · EBITDA exit · 5y419.81 – 463.48441.056% overvaluedDCF · EBITDA exit · 10y442.22 – 527.15482.663% undervaluedP/E · peers372.93 – 913.39446.554% overvaluedP/E · own history412.20 – 517.78452.893% overvaluedPEG—413.1913% overvaluedEV/EBITDA · peers343.31 – 933.65541.9614% undervaluedEV/Revenue · peers277.22 – 766.89398.1217% overvaluedEarnings power value149.05 – 278.87199.81133% overvaluedDividend discount193.32 – 553.60298.4256% overvaluedWall St. consensus target—412.5013% aboveCost of capital (WACC)—6.88%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
530.46
Amgen closed at $466.01 — undervalued by 12% vs model.
406.96the model's range739.82
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
199.81 – 559.19
Wall St. target
412.50 13% above
Below model, 1y
4 of 31 days
How it is valued
Valued asMature & stable
Moderate growth (~14% recent)High profitability (21% net margin)Pays dividendsHighly cyclical earningsHigh leverage (D/E 6.3x)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.